(RTTNews) – Celltrion, Inc. (068270.KS), a biopharmaceutical company, on Friday reported higher operating income and sales in the second quarter of 2026 compared with the same period last year.
For the second quarter, operating income also jumped to KRW 751.9 billion from KRW 391.9 billion
Sales for the period increased to KRW 2.45 trillion from KRW 1.80 trillion in the previous year.
Celltrion closed trading 3.96% higher at KRW 183,600 on the Korean Stock Exchange.
Eagle One Intelligence
Macro shifts, market structure, and the ideas worth tracking — straight to your inbox.
Note. For informational purposes only. Not financial advice. Past performance does not guarantee future results.
In recent trading, shares of Kimberly-Clark Corp. (Symbol: KMB) have crossed above the average analyst 12-month target price of $130.31,…
CrowdStrike stock (NASDAQ: CRWD) looked like it had fallen off a cliff on Thursday, with the stock moving from roughly…
Key Points If you’re planning to retire in 2027, it’s time to start thinking about what you’ll do with your…
The latest episodes, articles, and market insights, delivered to your inbox. No noise, just signal.
Join 25,000+ readers. No spam, ever.
Eagle One Intelligence
Macro shifts, market structure, and the ideas worth tracking — straight to your inbox before the crowd figures it out.
